Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma Inc (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering novel CAR-T therapies and Tissue-Specific Therapeutics™ for hematologic cancers and autoimmune disorders. This page serves as the definitive source for verified corporate announcements, clinical development updates, and regulatory milestones.
Investors and researchers will find chronologically organized press releases detailing clinical trial results, FDA designations, and strategic partnerships. Our collection includes updates on lead candidates like NXC-201 for AL Amyloidosis and IMX-110 for soft tissue sarcoma, featuring their unique Single-Day CRS profiles and TME Normalization Technology advancements.
All content is curated to provide stakeholders with essential insights into the company’s progress in addressing unmet medical needs through innovative cell therapies. Regular updates ensure access to the latest information on trial phases, scientific publications, and intellectual property developments.
Bookmark this page for streamlined tracking of Immix Biopharma’s advancements in next-generation immunotherapy and biopharmaceutical research.
Immix Biopharma (NASDAQ: IMMX) has expanded its U.S. clinical trial sites for the NEXICART-2 study, evaluating CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients. New sites include Cleveland Clinic, UC Davis, and Sutter Health, joining lead site Memorial Sloan Kettering Cancer Center. This expansion aims to increase patient access and enrollment opportunities across the U.S.
The study builds on positive data from the ex-U.S. NEXICART-1 trial, which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. NXC-201 is currently the only CAR-T therapy in development for AL Amyloidosis. The expansion supports upcoming interim and final read-outs of NEXICART-2, as Immix Biopharma continues its mission to advance treatment options for this patient population.
Immix Biopharma (Nasdaq: IMMX) has been awarded an $8 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of NXC-201, a CAR-T cell therapy for relapsed/refractory AL Amyloidosis. The funding will be used for the NEXICART-2 U.S. clinical trial, which aims to evaluate the safety and efficacy of NXC-201 in patients with adequate cardiac function who have not received prior BCMA-targeted therapy.
The decision follows promising results from the ex-U.S. NEXICART-1 study, which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. NXC-201 is currently the only CAR-T therapy in development for AL Amyloidosis, a rare disease with treatment options. The therapy's potential has been recognized in a recent New England Journal of Medicine review article.
Immix Biopharma has dosed the first patient in its U.S. NEXICART-2 trial for AL Amyloidosis at Memorial Sloan Kettering Cancer Center. The trial aims to assess the safety and efficacy of NXC-201, a BCMA-targeted CAR-T cell therapy, in patients with relapsed or refractory AL Amyloidosis. This follows positive results from the ex-U.S. NEXICART-1 trial, which showed a 92% overall response rate. The trial's initiation is in line with Immix Biopharma's mid-2024 guidance. NXC-201 could become a first-in-class treatment for AL Amyloidosis, with no approved drugs currently available for relapsed cases.
Immix Biopharma, a clinical-stage biopharmaceutical company, announced their participation in the Stifel 2024 Cell Therapy Forum on July 9, 2024. The event will be held virtually, where Immix Biopharma will present and host institutional investor meetings. The company specializes in developing cell therapies for autoimmune diseases and aims to engage with institutional investors during this forum to discuss their advancements and business strategies.
Immix Biopharma, Inc. announced positive clinical data for NXC-201 in treating relapsed/refractory AL Amyloidosis patients, showcasing a 92% overall response rate with 75% complete responders. The impressive response rates and durability of the treatment highlight its potential as a new option for patients. The company plans to proceed with the NEXICART-2 clinical trial in mid-2024 based on the positive outcomes of the NEXICART-1 study.
Immix Biopharma, Inc. has been granted European Orphan Drug Designation for NXC-201 in the treatment of multiple myeloma, providing 10 years of market exclusivity, access to centralized authorization procedure, and reduced fees for various applications. The Company aims to address unmet medical needs in frail patients with relapsed/refractory multiple myeloma, with potential benefits in terms of tolerability and clinical impact. The designation signifies recognition of the therapy's potential for this patient population, opening up opportunities for further development.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
